{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:19:06Z","timestamp":1792405146087,"version":"4.4.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009996","name":"Shaanxi Province Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010246","name":"Postdoctoral Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011002","name":"National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Biophysics and Molecular Biology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.pbiomolbio.2019.11.007","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:19:09Z","timestamp":1574327949000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"special_numbering":"C","title":["Recent treatment progress of triple negative breast cancer"],"prefix":"10.1016","volume":"151","author":[{"given":"Yang","family":"Chang-Qing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Shi-Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Zi-Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Hui-Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Ren-Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Da-Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Chen-Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A\u00a0road map for those who don\u2019t know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib2","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2010.33.4714","article-title":"Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy","volume":"29","author":"Abdulkarim","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib3","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1245\/s10434-011-1920-z","article-title":"Triple-negative breast cancer is not a contraindication for breast conservation","volume":"18","author":"Adkins","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1940-6207.CAPR-14-0225","article-title":"A\u00a0novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood\u2013brain barrier","volume":"8","author":"Adkins","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10585-016-9784-z","article-title":"Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer","volume":"33","author":"Adkins","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.soc.2014.03.003","article-title":"Basal-like and triple-negative breast cancers: searching for positives among many negatives","volume":"23","author":"Alluri","year":"2014","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nm.2795","article-title":"Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance","volume":"18","author":"Balko","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib9","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1172\/JCI75661","article-title":"Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth","volume":"124","author":"Barbie","year":"2014","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","article-title":"Targeting PI3 kinase in cancer","volume":"146","author":"Bauer","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/1878-0261.12446","article-title":"Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death","volume":"13","author":"Beltr\u00e1n-Anaya","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib15","doi-asserted-by":"crossref","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","article-title":"Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies","volume":"7","author":"Blows","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib16","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair pathway choices and consequences at the double-strand break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1757-2215-6-41","article-title":"Sulforaphane induced cell cycle arrest in the G2\/M phase via the blockade of cyclin B1\/CDC2 in human ovarian cancer cells","volume":"6","author":"Chang","year":"2013","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/15384047.2015.1040957","article-title":"Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer","volume":"16","author":"Chen","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib22","doi-asserted-by":"crossref","first-page":"114588","DOI":"10.18632\/oncotarget.23055","article-title":"CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2\u03b1-ATF4 pathway","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib23","first-page":"e1205","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Clin. Breast Canc."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/0008-5472.CAN-13-2175","article-title":"Targeting Akt3 signaling in triple-negative breast cancer","volume":"74","author":"Chin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1535-7163.MCT-12-0781","article-title":"Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities","volume":"12","author":"Craig","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib26","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"De Luca","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00018-019-03033-4","article-title":"IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer","volume":"76","author":"de Silva","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib28","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.18632\/oncotarget.4433","article-title":"The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer","volume":"6","author":"Deben","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib29","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/CAD.0000000000000202","article-title":"Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K\/AKT\u2013mTOR pathway","volume":"26","author":"Deng","year":"2015","journal-title":"Anti Canccer Drugs"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib31","doi-asserted-by":"crossref","first-page":"21138","DOI":"10.3390\/ijms160921138","article-title":"PI3K and AKT: unfaithful partners in cancer","volume":"16","author":"Faes","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib32","first-page":"953","article-title":"miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN","volume":"9","author":"Fang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib34","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl.\u00a08","key":"10.1016\/j.pbiomolbio.2019.11.007_bib35","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamasurg.2013.3037","article-title":"Breast-conserving therapy for triple-negative breast cancer","volume":"149","author":"Gangi","year":"2014","journal-title":"JAMA Surg."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40262-017-0587-4","article-title":"PARP inhibitors in the treatment of triple-negative breast cancer","volume":"57","author":"Geenen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib38","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41388-018-0586-4","article-title":"The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers","volume":"38","author":"Gooding","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib39","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/onc.2010.386","article-title":"miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness","volume":"29","author":"G\u00f6tte","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib40","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib41","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10585-016-9835-5","article-title":"In\u00a0vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer","volume":"34","author":"Hamilton","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib44","doi-asserted-by":"crossref","first-page":"11756","DOI":"10.18632\/oncotarget.7598","article-title":"Functional interactions of the cystine\/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells","volume":"7","author":"Hasegawa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2018.00575","article-title":"Notch signaling regulates mitochondrial metabolism and NF-\u03baB activity in triple-negative breast cancer cells via IKK\u03b1-dependent non-canonical pathways","volume":"8","author":"Hossain","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.15252\/emmm.201707779","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"9","author":"Iorio","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib49","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1002\/jcp.26470","article-title":"NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1","volume":"233","author":"Jiang","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib50","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1038\/onc.2012.517","article-title":"Non-canonical Notch signaling activates IL-6\/JAK\/STAT signaling in breast tumor cells and is controlled by p53 and IKK\u03b1\/IKK\u03b2","volume":"32","author":"Jin","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12032-017-1071-6","article-title":"Immunotherapy in triple-negative breast cancer","volume":"35","author":"Katz","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00432-005-0668-x","article-title":"Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy","volume":"131","author":"Kaufmann","year":"2005","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib56","first-page":"11","article-title":"NEAT1 is Required for Survival of breast cancer Cells through FUS and miR-548","volume":"10","author":"Ke","year":"2016","journal-title":"Gene Regul. Syst. Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging the p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Khoo","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:CLIN.0000024761.00373.55","article-title":"Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice","volume":"21","author":"Kim","year":"2004","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib59","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1471-4914(02)02298-0","article-title":"Caretaker tumour suppressor genes that defend genome integrity","volume":"8","author":"Levitt","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib62","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3892\/ijo.2016.3319","article-title":"Downregulation of beta3 integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk\/Ets1 network in triple-negative breast cancer","volume":"48","author":"Li","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13058-017-0918-2","article-title":"miR-105\/93-3p promotes chemoresistance and circulating miR-105\/93-3p acts as a diagnostic biomarker for triple negative breast cancer","volume":"19","author":"Li","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib64","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrendo.2010.92","article-title":"Molecular therapy of breast cancer: progress and future directions","volume":"6","author":"Lin","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/onc.2012.538","article-title":"The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents","volume":"33","author":"Lin","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1\u03b1 signaling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib67","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr3148","article-title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/dna.2016.3282","article-title":"microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7","volume":"35","author":"Liu","year":"2016","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib70","doi-asserted-by":"crossref","first-page":"39559","DOI":"10.18632\/oncotarget.17136","article-title":"Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib71","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.12659\/MSM.907256","article-title":"Study on the mechanism of cell cycle checkpoint kinase 2 (CHEK2) gene dysfunction in chemotherapeutic drug resistance of triple negative breast cancer cells","volume":"24","author":"Luo","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib72","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1002\/jcp.27906","article-title":"miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer","volume":"234","author":"Lv","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib73","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/jcb.25220","article-title":"EGFR and MEK blockade in triple negative breast cancer cells","volume":"116","author":"Maiello","year":"2015","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.breast.2007.11.031","article-title":"The prognostic importance of triple negative breast carcinoma","volume":"17","author":"Mersin","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv015","article-title":"Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights","volume":"107","author":"Ng","year":"2015","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib79","doi-asserted-by":"crossref","first-page":"15842","DOI":"10.1074\/jbc.M412891200","article-title":"Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1\/Jagged1-activated Notch1 signaling","volume":"280","author":"Nobta","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib80","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","article-title":"Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks","volume":"15","author":"Palmieri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib81","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"22","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib83","series-title":"Antiangiogenic Agents in Cancer Therapy","first-page":"225","article-title":"Lymphatic system in the pathology of cancer","author":"Pytowski","year":"2008"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib84","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1074\/jbc.M112.430082","article-title":"Acute mitochondrial inhibition by mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase (MEK) 1\/2 inhibitors regulates proliferation","volume":"288","author":"Ripple","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/JCO.1989.7.3.355","article-title":"A\u00a0long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma","volume":"7","author":"Rosen","year":"1989","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib86","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jpm.2011.0192","article-title":"Systematic review of cancer presentations with a median survival of six months or less","volume":"15","author":"Salpeter","year":"2011","journal-title":"J.\u00a0Palliat. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib87","first-page":"2108","volume":"379","author":"Schmid","year":"2018"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib88","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2000.18.8.1696","article-title":"Role of isolated locoregional recurrence of breast cancer: results of four prospective studies","volume":"18","author":"Schmoor","year":"2000","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib89","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib90","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajhg.2009.03.009","article-title":"Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia","volume":"84","author":"Shi","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/MCB.01016-12","article-title":"TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers","volume":"33","author":"Shields","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib92","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib93","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/abbs\/gmz021","article-title":"LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis","volume":"51","author":"Song","year":"2019","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib94","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib95","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-13-0830","article-title":"Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma","volume":"4","author":"Stoeck","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.277.5325.567","article-title":"Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B","volume":"277","author":"Stokoe","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib97","doi-asserted-by":"crossref","first-page":"28888","DOI":"10.1038\/srep28888","article-title":"Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pbiomolbio.2015.08.017","article-title":"Dynamics of P53 in response to DNA damage: mathematical modeling and perspective","volume":"119","author":"Sun","year":"2015","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib99","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1038\/onc.2016.394","article-title":"Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling","volume":"36","author":"Tang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biopha.2018.07.076","article-title":"Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer","volume":"107","author":"Tang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2407-8-228","article-title":"Imagable 4T1 model for the study of late stage breast cancer","volume":"8","author":"Tao","year":"2008","journal-title":"BMC Canc."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-7-134","article-title":"Use of immunohistochemical markers can refine prognosis in triple negative breast cancer","volume":"7","author":"Tischkowitz","year":"2007","journal-title":"BMC Canc."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib104","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib105","first-page":"806","article-title":"Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas","volume":"5","author":"Ueng","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib106","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/acs.bioconjchem.9b00028","article-title":"Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy","volume":"30","author":"Vaidya","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib107","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-016-3757-4","article-title":"Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study","volume":"156","author":"van Roozendaal","year":"2016","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib108","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nox052","article-title":"Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer","volume":"19","author":"Van Swearingen","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib111","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/cncr.11143","article-title":"Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?","volume":"97","author":"Vicini","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib112","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib113","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib114","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1002\/jcp.26311","article-title":"Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): expression analysis and biological roles research","volume":"233","author":"Wang","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib115","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1002\/jcp.28007","article-title":"Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p\/HOXC6 signaling pathway","volume":"234","author":"Wang","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib116","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2009.166","article-title":"Histological and molecular types of breast cancer: is there a unifying taxonomy?","volume":"6","author":"Weigelt","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib117","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib118","first-page":"422","article-title":"Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer","volume":"24","author":"Wu","year":"2016","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib119","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2017.04.023","article-title":"A\u00a0novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer","volume":"400","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10549-012-2398-5","article-title":"High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival","volume":"137","author":"Yamada","year":"2013","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1476-4598-13-220","article-title":"miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer","volume":"13","author":"Yan","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib122","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/09168451.2019.1588097","article-title":"LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9","volume":"83","author":"Yang","year":"2019","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib123","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1038\/s41598-018-23999-8","article-title":"The prognostic value of nodal staging in triple-negative breast cancer - a cohort from China","volume":"8","author":"Yin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib124","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","article-title":"A\u00a0bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in\u00a0vivo and in\u00a0vitro","volume":"16","author":"Yoneda","year":"2001","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijerph14010068","article-title":"New immunotherapy strategies in breast cancer","volume":"14","author":"Yu","year":"2017","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib126","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1038\/sj.onc.1210420","article-title":"BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers","volume":"26","author":"Yuli","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tcb.2013.09.007","article-title":"Microenvironmental regulation of cancer metastasis by miRNAs","volume":"24","author":"Zhang","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10495-016-1214-9","article-title":"Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells","volume":"21","author":"Zhang","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib129","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3389\/fphar.2018.01248","article-title":"AFAP1-AS1 promotes epithelial-mesenchymal transition and tumorigenesis through wnt\/\u03b2-catenin signaling pathway in triple-negative breast cancer","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib130","doi-asserted-by":"crossref","first-page":"43517","DOI":"10.1038\/srep43517","article-title":"WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancer s to overcome cisplatin resistance","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib131","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/oncsis.2017.58","article-title":"miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and \u03b11,3-fucosylated glycans","volume":"6","author":"Zheng","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.pbiomolbio.2019.11.007_bib132","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1245\/s10434-013-3011-9","article-title":"Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer","volume":"20","author":"Zumsteg","year":"2013","journal-title":"Ann. Surg. Oncol."}],"container-title":["Progress in Biophysics and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079610719301282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079610719301282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:47:07Z","timestamp":1758750427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079610719301282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":128,"alternative-id":["S0079610719301282"],"URL":"https:\/\/doi.org\/10.1016\/j.pbiomolbio.2019.11.007","relation":{},"ISSN":["0079-6107"],"issn-type":[{"value":"0079-6107","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent treatment progress of triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Progress in Biophysics and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbiomolbio.2019.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}